Korneuburg, Austria, July 16th, 2026 – Marinomed Biotech AG (VSE:MARI) announces the plan to apply for the initiation of a court restructuring proceeding without selfadministration. The application is being filed because the court-approved restructuring plan dated November 14, 2024, cannot be fulfilled due to the breakdown of negotiations by Unither and the failure of Unither Pharmaceuticals to make earn-out payments from the sale of the Carragelose business unit, thereby placing the company at risk of insolvency. The aim of the renewed restructuring proceedings without self-administration is to secure the company's financial stability by concluding a new restructuring plan. In addition to further restructuring measures, the legal options available against Unither arising from the sale of the Carragelose business and the assets of the Marinosolv platform are to be utilized.
+++ End of ad-hoc announcement +++